Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

progesterone

CRINONE 8%

progesterone (CRINONE 8%) is a progesterone receptor agonist. Associated with Orion Laboratories Pty.. Route of administration: injection. Current US regulatory status: approved.

FDA: approved TGA: approved NMPA: clinical trials
US status approved
Patents linked 20
Pipeline programs 27
News articles 0
Drug details — progesterone
US status
approved
Class
—
Route
INJECTION
Patents
20
Programs
27
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

progesterone (CRINONE 8%) is a progesterone receptor agonist. Associated with Orion Laboratories Pty.. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN progesterone
Brand CRINONE 8%
Mechanism Progesterone receptor agonist
Target Progesterone receptor
Route INJECTION
Formulation CAPSULE
Originator Orion Laboratories Pty.

Mechanism of action

Progesterone receptor agonist

Primary target: Progesterone receptor

Approval history

Authority Status Date
FDA approved —
TGA approved —
NMPA clinical trials —

Pipeline programs

Search pipeline Sponsor programs
  1. MK-5684-015 Phase 3 · MSD Merck Sharp · Breast cancer, Ovarian cancer, Endometrial cancer
  2. Oral micronized progesterone Phase 3 · BRIGHT MINDS BIOSCIENCES · Cocaine Dependence
  3. Progesterone Phase 3 · TherapeuticsMD · Secondary Amenorrhea
  4. Progesterone Phase 3 · United Therapeutics Europe · Alcohol Dependence
  5. Progesterone supplementation Phase 3 · Hospital Authority · Assisted Reproductive Technology
  6. didroxyprogesterone Phase 3 · First People's Hospital · Pregnancy Rate
  7. 9941 Phase 2 · CNS Pharmaceuticals · Menopause
  8. D933LC00001 Phase 2 · AstraZeneca · First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC

Related & competitor drugs

Browse all drugs
  1. desogestrel Progesterone receptor agonist
  2. medroxyprogesterone acetate Progesterone receptor agonist
  3. megestrol acetate Progesterone receptor agonist
  4. norethindrone Progesterone receptor agonist
  5. norethindrone acetate Progesterone receptor agonist
  6. ulipristal acetate Genito-urinary system and sex hormones (G03)

Related patents

Browse patents Orion Laboratories Pty. patent hub

  1. US 11865179

    Progesterone formulations having a desirable PK profile

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11793819

    Natural combination hormone replacement formulations and therapies

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11529360

    Natural combination hormone replacement formulations and therapies

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11166963

    Natural combination hormone replacement formulations and therapies

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11135154

    Medroxyprogesterone acetate injectable compositions and methods of use

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11110099

    Natural combination hormone replacement formulations and therapies

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11103513

    Natural combination hormone replacement formulations and therapies

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11033626

    Progesterone formulations having a desirable pk profile

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10942183

    Methods of detecting progesterone receptor and of detecting an expression level

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10806740

    Natural combination hormone replacement formulations and therapies

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10675288

    Natural combination hormone replacement formulations and therapies

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10639375

    Progesterone formulations

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10471148

    Progesterone formulations having a desirable PK profile

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10206932

    Natural combination hormone replacement formulations and therapies

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10052386

    Progesterone formulations

    Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9301920

    Natural combination hormone replacement formulations and therapies

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9114145

    Natural combination hormone replacement formulations and therapies

    Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9114146

    Natural combination hormone replacement formulations and therapies

    Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9006222

    Natural combination hormone replacement formulations and therapies

    Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8993549

    Natural combination hormone replacement formulations and therapies

    Expires Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is progesterone?

progesterone (CRINONE 8%) is a progesterone receptor agonist. Associated with Orion Laboratories Pty.. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for progesterone?

CRINONE 8% is a marketed brand name for progesterone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of progesterone?

progesterone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.